Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Gains from Investment Securities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Gains from Investment Securities for 15 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 14568.75% to -$2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.1 million, a 2230.83% increase, with the full-year FY2024 number at $3.2 million, up 4.24% from a year prior.
  • Gains from Investment Securities was -$2.3 million for Q3 2025 at Usana Health Sciences, down from $2.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.2 million in Q2 2022 to a low of -$3.1 million in Q2 2024.
  • A 5-year average of $589866.7 and a median of $134000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 9059.57% in 2022, then crashed 14568.75% in 2025.
  • Usana Health Sciences' Gains from Investment Securities stood at -$47000.0 in 2021, then skyrocketed by 419.15% to $150000.0 in 2022, then dropped by 10.67% to $134000.0 in 2023, then skyrocketed by 2305.97% to $3.2 million in 2024, then plummeted by 171.81% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Gains from Investment Securities are -$2.3 million (Q3 2025), $2.2 million (Q2 2025), and $3.2 million (Q4 2024).